Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteer study aims to sharpen future diagnostic tests

NCT ID NCT05160337

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how stable certain biomarkers (like RNA and proteins) are in healthy volunteers. Researchers want to see if things like age, gender, or eating affect these markers. The goal is to make future diagnostic tests more reliable. The study involves 60 healthy adults aged 18 to 85.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Biomarker based IVD tests
What this could lead to
If successful, this could help create more reliable diagnostic tests for various diseases by understanding how biomarkers behave in healthy people.
What could go wrong
This is a small, early-stage study in healthy volunteers only, so results may not apply to people with diseases. It does not test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who sign the informed consent forms for sample collection and data collection both anonymized and reported in CRF. * Able to comply with all study procedures. * Healthy Volunteers having no apparent disease. * Adults, both genders, aged 18-85 years. * Participants with no apparent motor or mental health abnormality. * Participants having no major disabling mental or physical disability that would require hospitalization. * Body weight above 50 kg if male, above 40 kg if female. Exclusion Criteria: * Any subject who did not sign the Informed Consent form. * Any subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development. * Any subject in the exclusion period of a previous study according to applicable regulations. * Any subject who cannot be contacted in case of emergency. * Any subject who is the Investigator or any sub-investigator, research assistant, study coordinator, or other staff thereof, directly involved in the conduct of the protocol. * Any subject with a disease that, in the judgement of the investigator, would interfere with the conduct of study or harm the safety of volunteer. * Subjects with disabling disease or abnormal health status are excluded. * Subjects aged below 18 years and older than 85 years are excluded. * Pregnant, parturient and nursing women are excluded. * Subjects deprived of their liberty by a judicial or administrative decision, protected adults and vulnerable persons are excluded. * Subjects who are under legal protection or who are unable to express their consent are not included. * Any subject who reports in the questionnaire of the screening period having one of the following diseases is excluded: * Any psychiatric or neurodegenerative disease or neurologic disorder. * Hypertension. * Any cardiovascular disease. * Any chronic inflammatory disease such as rheumatoid arthritis. * Any cancer. * Frequent headaches and/or migraine, recurrent nausea and/or vomiting. * Any subject who did a blood donation, any volume, within 2 months before inclusion. * Any subject who reports in the questionnaire of the screening period having medication(s) for one or more of the above diseases is excluded. * Drug or alcohol abuse or smoking more than 10 cigarettes or equivalent. * Subjects with no apparent disease and symptoms, but with unknown Covid-19 positivity are not excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Firalis Clinical Investigation Center

    RECRUITING

    Huningue, 68330, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.